Sarmad Sadeghi
University of Southern California · SWOG Cancer Research Network · City of Hope Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sarmad Sadeghi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:46 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT06493552 · Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsVasgene Therapeutics, Inc · recruiting · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma · principal investigator
- Ph3NCT04579224 · Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerNational Cancer Institute (NCI) · active not recruiting · Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma · principal investigator
- Ph2NCT04486781 · A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial CarcinomaVasgene Therapeutics, Inc · unknown · Metastatic Urothelial Carcinoma · principal investigator
- Ph2NCT03092856 · Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney CancerUniversity of Southern California · active not recruiting · Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma · principal investigator
- Ph2NCT02717156 · Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsUniversity of Southern California · active not recruiting · Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma · principal investigator
- Ph2NCT02178241 · Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.R01CA293348 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2025 to 2026 · $679,846 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2019 to 2026Named on NCT04579224
- Cancer Research Training and Education CoordinationP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Josh Neman-Ebrahim · fiscal years 2018 to 2026Named on NCT03092856, NCT02717156
- Integrated Cancer Biology ProgramP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Wolf-Dietrich Heyer · fiscal years 2018 to 2026Named on NCT02178241
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:46 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.J Clin Oncol · 2009788 citationsRCR 16.4
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol · 2018541 citationsRCR 17.7
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol Hepatol · 2021357 citationsRCR 19.4
- Etanercept therapy in children with treatment-resistant uveitis.Arthritis Rheum · 2001218 citationsRCR 7.2
- 131 citationsRCR 2.9
- N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.Clin Neuropharmacol · 2013125 citationsRCR 4.6
- Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions.Radiother Oncol · 201389 citationsRCR 3.0
- Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.Future Oncol · 202082 citationsRCR 3.4
- Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers.Stem Cell Res Ther · 202259 citationsRCR 5.7
- 52 citationsRCR 1.4